Manufacturers report efbemalenograstim alpha hits primary and secondary endpoints in phase III trial

In this study, manufacturers report that efbemalenograstim alfa (a novel long-acting G-CSF) hit primary and secondary non-inferiority endpoints in a comparative trial with pegfilgrastim for treatment of chemotherapy induced neutropenia in breast cancer patients.

Source:

Biospace Inc.